KRAS and non-small cell lung carcinoma: DCs engineered against mutant KRAS were efficacious when injected into mouse models of NSCLC, and a clinical trial applying this principle to humans has entered Phase I targeting KRAS G12C, G12D, G12R, and G12V [93].